The company’s patent portfolio covers more than 20 issued patents and patent applications in various territories. In addition, Synvolux maintains and continues to expand its proprietary OptiSAINT™ library, containing a large number of formulations comprising different SAINT lipids, helper lipids, and accessory compounds for optimized transfection of specific cell types. Saint-o-somes™ are patented, SAINT-based immuno-liposomes for in vitro and in vivo purposes which may be tailored to release their cargo (e.g. DNA, RNA, protein/peptides) to specific cell types or tissues through antibody-directed targeting. If you are interested in licensing our technologies, then please contact us.
Synvolux is also open to in-licensing opportunities. If you have developed a novel technology that complements our products, and/or if you are looking for a partner to help you develop or commercialize innovations, then feel free to discuss partnering options with us.